trial summary · NCT07808450
Nitazoxanide in Spontaneous Bacterial Peritonitis
Evaluation of Nitazoxanide as Adjunctive Therapy for Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis: A Randomized Controlled Clinical Trial Protocol
Trial record from the TrialBase DB dataset, status RECRUITING, condition SBP - Spontaneous Bacterial Peritonitis, sponsored by Tanta University. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
Spontaneous bacterial peritonitis (SBP) is a life-threatening complication of liver cirrhosis characterized by infection of ascitic fluid in the absence of an evident intra-abdominal source. SBP occurs in approximately 10-30% of hospitalized cirrhotic patients with ascites and is associated with high short-term mortality despite advances in antimicrobial therapy. ¹˒² The pathogenesis of SBP is multifactorial and involves gut microbiota dysbiosis, increased intestinal permeability, bacterial translocation, and impaired host immune defenses. ³ Translocation of gut-derived bacteria and endotoxins, particularly lipopolysaccharides (LPS), activates systemic inflammatory pathways, promotes circulatory dysfunction, and predisposes patients to recurrent SBP episodes. ⁴˒⁵ Current management of SBP relies on empirical broad-spectrum antibiotics, most commonly third-generation cephalosporins, along with albumin infusion. ⁶ However, the increasing prevalence of multidrug-resistant organisms, recurrent SBP, and antibiotic-related adverse effects has created an urgent need for novel adjunctive or preventive strategies. ⁷ Nitazoxanide (NTZ) is a thiazolide derivative with broad-spectrum antibacterial, antiparasitic, and antiviral properties. In addition to its antimicrobial activity, NTZ has demonstrated anti-inflammatory effects, inhibition of nuclear factor-κB (NF-κB) signaling, and improved intestinal epithelial barrier integrity. ⁸˒⁹ Experimental data suggest that NTZ reduces gut permeability and systemic endotoxemia, mechanisms that are directly implicated in the development and …
Source record: https://clinicaltrials.gov/study/NCT07808450
Facts
| registry id | NCT07808450 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1/PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | SBP - Spontaneous Bacterial Peritonitis |
| sponsor | Tanta University |
| sponsor class | OTHER |
| enrollment | 60 |
| start date | 2026-10-25 |
| primary completion | 2027-06-01 |
| completion | 2027-06-01 |
| results posted | not reported |
Conditions
- SBP - Spontaneous Bacterial Peritonitis
Interventions
- Nitazoxanide (NTZ)
- Placebo
Countries
- Egypt
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.